Elekta Receives FDA 510 (k) Clearance For Monaco VMAT Treatment Planning Solution

Main Category: Radiology / Nuclear Medicine
Also Included In: Regulatory Affairs / Drug Approvals;  Cancer / Oncology
Article Date: 27 Jul 2009 - 15:00 PDT

email to a friend   printer friendly   opinions  

Elekta (STO:EKTAB) has received FDA 510(k) clearance for the VMAT (Volumetric Modulated Arc Therapy) enhancement to Monaco®, treatment planning solution.

Monaco treatment planning system, introduces a set of tools to make the treatment planning process easier, more straightforward and clinically reliable. For the clinicians this gives the flexibility and control needed for complex treatment. For the clinic administrator it provides reduced planning time and increased clinical throughput.

"We are extremely proud and very pleased to receive clearance to add this VMAT technique to Monaco in the U.S. market," said Rob Cessac, Product Manager for Elekta CMS Software. "Our continued support and development of leading approaches to cancer treatment promises to create a positive future for clinicians and patients."

The biologically-based Monaco IMRT (Intensity Modulated Radiotherapy) treatment planning system features constrained optimization and dose calculation algorithms and help reduce the time needed to optimize IMRT plans.

Monaco has been available for use clinically for the past two years for step-and-shoot IMRT planning. The product was developed in cooperation with Eberhard Karls University Tuebingen in Germany. For the latest Monaco with VMAT news, visit http://www.elekta.com.

Source
Elekta

• Additional
• References
• Citations